奥那妥珠单抗

奥那妥珠单抗
单克隆抗体
种类	Fab片段（英语：Fab fragment）
目标	散射因子受体激酶
临床资料
ATC码	未分配;
识别信息
CAS号	1133766-06-9
ChemSpider	none;
UNII	MS1J9720WC;
化学信息
化学式	C4422H6820N1168O1363S31
摩尔质量	99,147.88 g·mol−1

奥那妥珠单抗（INN：onartuzumab）是一种人源化单克隆抗体，设计用于治疗晚期非小细胞肺癌。^[1]^[2]^[3]

奥那妥珠单抗由基因泰克公司开发，正在进行临床试验。^[4]^[5]^[6]^[7]

参考资料

^ Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab (PDF). American Medical Association. [2024-03-15]. （原始内容存档 (PDF)于2015-07-23）.
^ Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res. December 2012, 1 (4): 238–53. PMC 4367550 . PMID 25806189. doi:10.3978/j.issn.2218-6751.2012.10.08.
^ Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: the fall of Icarus?. Expert Rev Anticancer Ther. May 2015, 15 (5): 487–9. PMID 25818471. doi:10.1586/14737140.2015.1031219 .
^ Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol. November 2013, 53 (11): 1103–11. PMID 23922054. S2CID 206059437. doi:10.1002/jcph.148.
^ Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. Clin Lung Cancer. November 2012, 13 (6): 500–4. PMID 23063071. doi:10.1016/j.cllc.2012.05.009.
^ Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. November 2013, 31 (32): 4105–14. PMC 4878106 . PMID 24101053. doi:10.1200/JCO.2012.47.4189.
^ Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs. June 2015, 33 (3): 632–40. PMID 25777467. S2CID 20118425. doi:10.1007/s10637-015-0227-5.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council: Onartuzumab (PDF). American Medical Association. [2024-03-15]. （原始内容存档 (PDF)于2015-07-23）.

[2] Padda S, Neal JW, Wakelee HA. MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res. December 2012, 1 (4): 238–53. PMC 4367550 . PMID 25806189. doi:10.3978/j.issn.2218-6751.2012.10.08.

[3] Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. Onartuzumab in lung cancer: the fall of Icarus?. Expert Rev Anticancer Ther. May 2015, 15 (5): 487–9. PMID 25818471. doi:10.1586/14737140.2015.1031219 .

[4] Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors. J Clin Pharmacol. November 2013, 53 (11): 1103–11. PMID 23922054. S2CID 206059437. doi:10.1002/jcph.148.

[5] Spigel DR, Edelman MJ, Mok T, O'Byrne K, Paz-Ares L, Yu W, Rittweger K, Thurm H. Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non-Small-Cell Lung Cancer. Clin Lung Cancer. November 2012, 13 (6): 500–4. PMID 23063071. doi:10.1016/j.cllc.2012.05.009.

[6] Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J. Clin. Oncol. November 2013, 31 (32): 4105–14. PMC 4878106 . PMID 24101053. doi:10.1200/JCO.2012.47.4189.

[7] Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs. June 2015, 33 (3): 632–40. PMID 25777467. S2CID 20118425. doi:10.1007/s10637-015-0227-5.

[1]

[2]

[3]

[4]

[5]

[6]

[7]